GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arecor Therapeutics PLC (LSE:AREC) » Definitions » Price-to-Free-Cash-Flow

Arecor Therapeutics (LSE:AREC) Price-to-Free-Cash-Flow : N/A (As of Jun. 14, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Arecor Therapeutics Price-to-Free-Cash-Flow?

As of today (2024-06-14), Arecor Therapeutics's share price is £1.275. Arecor Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was £-0.20. Hence, Arecor Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Arecor Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

LSE:AREC's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.085
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Arecor Therapeutics's Free Cash Flow per Share for the six months ended in Dec. 2023 was £-0.05. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was £-0.20.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -41.60% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -64.60% per year.

During the past 7 years, Arecor Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was -41.60% per year. The lowest was -137.10% per year. And the median was -60.40% per year.


Arecor Therapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Arecor Therapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arecor Therapeutics Price-to-Free-Cash-Flow Chart

Arecor Therapeutics Annual Data
Trend May17 May18 May19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial - - - - -

Arecor Therapeutics Semi-Annual Data
May18 May19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Arecor Therapeutics's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Arecor Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arecor Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arecor Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Arecor Therapeutics's Price-to-Free-Cash-Flow falls into.



Arecor Therapeutics Price-to-Free-Cash-Flow Calculation

Arecor Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=1.275/-0.196
=N/A

Arecor Therapeutics's Share Price of today is £1.275.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Arecor Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was £-0.20.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Arecor Therapeutics  (LSE:AREC) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Arecor Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Arecor Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Arecor Therapeutics (LSE:AREC) Business Description

Traded in Other Exchanges
Address
Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying an innovative proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Switzerland, the Rest of Europe, the USA, India, and the Rest of the World, out of which the majority is from the UK.

Arecor Therapeutics (LSE:AREC) Headlines